Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMKDP57)

• Drug Name: Safotibant Drug Info
• Synonyms: UNII-02HU8HWP7U; 02HU8HWP7U; 633698-99-4; CHEMBL1254771; LF22-0542; LF-22-0542; Safotibant [INN]; Lf 22-0542; SCHEMBL1723565; DTXSID20212769; BDBM50326708; N-((4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl)methyl)-2-(2-(((4-methoxy-2,6-dimethylphenyl)sulfonyl)methylamino)ethoxy)-N-methylacetamide; N-((4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl]methyl)-2-(2-((4-methoxy-2,6-dimethylbenzenesulfonyl)(methyl)amino]ethoxy)-N-methylacetamide; Acetamide, N-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)methyl)-2-(2-(((4-meth

Indication

Disease Entry	ICD 11	Status	REF
Diabetic macular edema	9B71.02	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 11953367
  CAS Number: CAS 633698-99-4
  TTD Drug ID: DMKDP57

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B1 bradykinin receptor (BDKRB1)	TTG5QIA	BKRB1_HUMAN	Modulator	[2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
B1 bradykinin receptor (BDKRB1)	DTT	BDKRB1	4.733	4.129	5.703	5.84

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Diabetic macular edema
• ICD Disease Classification: 9B71.02

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
B1 bradykinin receptor (BDKRB1)	DTT	BDKRB1	2.86E-01	0.54	0.35

References

• [1] ClinicalTrials.gov (NCT01319487) Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy. U.S. National Institutes of Health.
• [2] The role of kinin receptors in cancer and therapeutic opportunities. Cancer Letters Volume 345, Issue 1, 1 April 2014, Pages 27-38.